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ABSTRACT
Despite the great advance of bone tissue engineering in the last few years, repair of bone
defects remains a major problem. Low cell engraftment and dose-dependent side effects linked
to the concomitant administration of bone morphogenetic proteins (BMPs) are the main prob-
lems currently hindering the clinical use of mesenchymal stem cell (MSC)-based therapies in this
field. We have managed to bypass these drawbacks by combining the silencing the Smurf1
ubiquitin ligase in MSCs with the use of a scaffold that sustainably releases low doses of BMP-2.
In this system, Smurf1 silencing is achieved by using GapmeRs, a clinically safe method that
avoids the use of viral vectors, facilitating its translation to the clinic. Here, we show that a sin-
gle transient transfection with a small quantity of a Smurf1-specific GapmeR is able to induce a
significant level of silencing of the target gene, enough to prime MSCs for osteogenic differentia-
tion. Smurf1 silencing highly increases MSCs responsiveness to BMP-2, allowing a dramatic
reduction of the dose needed to achieve the desired therapeutic effect. The combination of
these primed cells with alginate scaffolds designed to sustainably and locally release low doses
of BMP-2 to the defect microenvironment is able to induce the formation of a mature bone
matrix both in an osteoporotic rat calvaria system and in a mouse ectopic model. Importantly,
this approach also enhances osteogenic differentiation in MSCs from osteoporotic patients, char-
acterized by a reduced bone-forming potential, even at low BMP doses, underscoring the regen-
erative potential of this system. STEM CELLS TRANSLATIONAL MEDICINE 2019;8:1306–1317
SIGNIFICANCE STATEMENT
The need to administrate high doses of bonemorphogenetic proteins (BMPs) to promote osteogene-
sis in certain orthopedic applications, along with their associated detrimental effects, is hindering the
clinical use of tissue engineering techniques in this particular field. Silencing of the Smurf1 gene in
mesenchymal stem cells (MSCs) by in situ transfecting these cells with an antisense oligonucleotide,
a clinically safe approach, significantly increases the susceptibility ofMSCs to BMP-2. The use ofMSCs
expressing low levels of Smurf1, together with biocompatible scaffolds that sustainably release low
doses of BMP in a controlled manner, might be able to promote bone formation, avoiding the harm-
ful effects linked to the presence of high concentration of BMPs in circulating blood.
INTRODUCTION
In recent years, there has been an increasing
interest in using mesenchymal stem cell (MSC)-
based approaches to improve bone repair and
regeneration [1]. In particular, the use of these
therapies would benefit the treatment of critical
size bone defects resulting from direct trauma
or from the removal of large bone areas through
surgical procedures in patients with osteosar-
coma, necrosis, or other pathologies. Although,
for many years, autologous bone grafts have
been the gold standard for the treatment of crit-
ical size bone defects, there are several draw-
backs associated to these procedures, such as
the limited tissue available for harvest, the
extended operative time required to surgically
obtain the graft, or the high percentage of mor-
bidity at donor site. Promotion of bone repair
through MSC-based therapies is a realistic
approach to circumvent these limitations.
Bone tissue engineering strategies require
an osteoconductive scaffold to support MSC
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such as bone morphogenetic proteins (BMPs), to promote MSC
differentiation. Among all BMPs analyzed, recombinant human
BMP-2 and BMP-7 (rhBMP-2 and rhBMP-7) have shown overall
positive results on promoting bone regeneration [2]. However,
BMPs are pleiotropic proteins that can exert their action on
nearby tissues producing unwanted effects such as ectopic bone
formation or swelling of soft tissue [3, 4]. Besides, a significant
number of studies suggest the existence of undesirable dose-
dependent side effects associated to the use of BMPs in the
clinical practice, such as an increase in inflammatory cells at the
site of application or the rise in serum levels of anti-BMP anti-
bodies [5–11]. Moreover, BMP doses beyond a certain threshold
could deregulate signaling pathways, promoting adipogenesis
over osteogenesis, leading to a reduced bone quality [12, 13].
These lingering problems emphasize the importance using scaf-
folds that sustainably release BMPs to allow the maintenance of
a minimal but adequate dose in the defect and to act as a guide
to improve the new tissue formation [14, 15].
Binding of a BMP homo or heterodimer to its receptor
activates downstream Smad proteins that translocate into the
nucleus, where they interact with Runx2, the master osteo-
genic regulator, to activate the expression of osteogenic genes
[16]. Since bone formation is a process subjected to strict reg-
ulation, once the Smad proteins have fulfilled their function,
they are ubiquitinated by the HECT-type ubiquitin ligase
Smurf1 (Smad ubiquitination regulatory factor 1), and subse-
quently degraded by the ubiquitin-proteasome system [17].
Besides its direct implication in flagging the Smad proteins for
destruction, Smurf1 seems to have an additional function lead-
ing to the suppression of bone formation, since this protein
would prevent osteoblast differentiation by decreasing the
accumulation of Runx2 in these cells, and their subsequent dif-
ferentiation [18].
An experimental approach that would greatly reduce the
BMP dose needed to activate bone formation, thus improving
the safety of the treatments, could be the abrogation of
Smurf1 expression to amplify the BMP signal. In fact, it has
been recently shown that overexpression of miR-503, a micro-
RNA targeting Smurf1, promotes bone formation both in vitro
and in vivo in a distraction osteogenesis model [19]. In fact,
our group has previously shown that knocking down Smurf1 in
rat MSCs (rMSCs) drastically increases bone formation [15].
However, although our systems proved to be highly effective
in achieving bone regeneration, it harbored important disad-
vantages that preclude its clinical application, such as the use
of viral vehicles that could integrate in the genome producing
mutations, the low stability of the siRNAs used for the silenc-
ing, or the off-target effect of these molecules, able to trigger
immune responses [20]. To overcome these important limita-
tions, we have developed a new method to achieve posttran-
scriptional gene silencing in MSCs based on the use of locked
nucleic acid antisense oligonucleotides (LNA-ASOs). These mol-
ecules can selectively and transiently regulate gene expression
and their use has proven to be both clinically safe and highly
effective [21, 22]. An LNA-ASO is a single-stranded deoxyribo-
nucleotide, typically 14–20 bp long, which can specifically bind
to its target mRNA directing its catalytic degradation through
the action of the RNase H, an endonuclease that specifically
recognizes DNA/RNA heteroduplexes and cleaves the RNA
strand [23]. A particular type of ASOs, the so-called GapmeRs,
has a specific design consisting of modified flanks to confer
improved stability and binding, and a central DNA gap suffi-
cient to induce RNase cleavage [24]. Currently, an important
disadvantage of the treatments based on the use of ASOs is
the high doses of these molecules needed to achieve the
desired therapeutic effect.
To achieve transient Smurf1 silencing through the use of
low doses of GapmeRs, we have successfully used a nontoxic
lipid-based delivery system [25] that highly promotes the
intake of those molecules by the cells through endocytosis,
making this process not only highly efficient but also economi-
cally affordable. The combination of MSCs where Smurf1
expression has been transiently silenced and a biocompatible
scaffold that sustainably release low BMP-2 doses represents a
promising and safe strategy for treating critical size fractures




Antisense LNA GapmeRs are 15-16-mer HPLC-purified DNA
antisense oligonucleotides with full phosphorothioate
(PS) substitutions (Exiqon, Qiagen, Venlo, the Netherlands).
The Smurf1 GapmeR used for silencing this gene in rats and
humans is complementary to a sequence located in exon 12.
As a negative control, we used Antisense LNA GapmeR Nega-
tive Control A (Ref. 300611-08). All GapmeRs were purchased
as molecules labeled with fluorescein (FAM) for their subse-
quent detection and quantification.
MSC Isolation
Rat mesenchymal stem cells (rMSCs) were obtained from
1-month-old female Sprague–Dawley following a protocol pre-
viously described [26]. Cells were passed when they reach
80% confluence. Early passages (passage 1 or 2) were
always used.
Human mesenchymal stem cells (hMSCs) were obtained
from bone marrow isolated from the femoral heads of patients
undergoing hip replacement surgery due to osteoporotic frac-
tures and characterized by flow cytometry as previously
described protocol [27]. All patients gave informed written
consent. Study protocol was approved by the institutional
review board (Comité de Etica en Investigación Clínica de
Cantabria).
Cell Culture and Differentiation
All primary MSCs obtained from bone marrow, regardless of
their origin (human or rat), were maintained in Mesempro RS
Media (Thermo Fisher Scientific, Waltham, MA). The murine
MSC line, C3H10T1/2, was cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM, Invitrogen, Carlsbad, CA, http://www.
invitrogen.com) supplemented with 10% FBS and 1% penicil-
lin/streptomycin. Cells were maintained under normoxic condi-
tions. To promote osteogenic differentiation, cells were plated
at 15 × 103 cell/cm2 in 24 well plates and allowed to attach
overnight. The following day, normal culture media was rep-
laced with induction medium (low glucose DMEM with 10%
FBS, 50 μm/ml ascorbic acid, 10 mM β-glycerophosphate,
100 nM dexamethasone) for the required time. The same
www.StemCellsTM.com © 2019 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
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induction media was used for all primary MSCs and the
C3H10T1/2 cell line.
Flow Cytometry
Cells were analyzed in a FACSCanto II flow cytometer using
FACSDiva Software (BD Biosciences, San Diego, CA, http://
www.bdbiosciences.com). Antibodies for human MSCs charac-
terization have already been described [27]. The delivery effi-
ciency of each GapmeR into cells was determined using FAM-
labeled Gapmers. A minimum of 105 cells were harvested at
indicated time points, washed in phosphate buffered solution
(PBS) and resuspended in FACS Buffer (PBS, 5% Fetal Bovine
Serum and 0.1% Sodium Azide) before analysis in the
cytometer.
Alginate Scaffolds and Microsphere Preparation
To prepare the alginate scaffolds, 15 mg of microspheres were
dispersed in 100 μl of 2% alginate (Pronova UP-MVG) in sterile
MiliQ water. Then, the suspension was freeze-dried, cross-
linked by incubation with a 0.15% CaCl2, and after three
washed with sterile MilliQ water, freeze-dried again. All the
systems were stored at 4C until use. The size and shape of
the scaffolds are shown in Supplementary Figure S1. Micro-
spheres encapsulating different amounts of rhBMP-2
(Biomedal Life Sciences, Sevilla, Spain) were fabricated by the
previously described double emulsion method under aseptic
conditions [15]. Briefly, 200 μl of rhBMP-2 in 0.07% polyvinyl
alcohol (PVA) were mixed, using vortex (Vortex-Genie 2, Scien-
tific Industries Inc., Bohemia, NY), with 2 ml of a PLGA
(Resomer RG504, Evonik, Germany) methylene chloride solu-
tion (50 mg/ml). Then, the mix was poured into 100 ml of a
0.1% PVA (w/v) solution under constant, magnetic stirring
(2 hours) for the organic solvent evaporation. Microspheres
were filtered and lyophilized. Some batches were prepared
with 125I-BMP-2 (Perkin-Elmer) to determine rhBMP-2 encap-
sulation efficiency (71%  6%). Microspheres were visualized
by scanning electron microscopy (SEM, Jeol JSM-6300)
(Supplementary Fig. S1) and the microsphere volume diameter
(μm) distribution, determined by laser diffractometry using a
Mastersizer 2000 (Malvern Instruments) was: <76.6 (10%),
<102.5 (50%), and <193.5 (90%).
In vitro release assays were carried out using 125I-BMP-2
as a tracer. Briefly, each scaffold was incubated separately in a
solution of PBS at 37C under orbital shaking at 50 rpm. The
amount of BMP-2 released was calculated by measuring sam-
ple radioactivity at each time point.
Cell Transfection and Smurf1 Silencing
To enhance the cellular uptake of the GapmeRs, we used a
lipid transfection agent (Dharmafect, Dharmacon, Horizon Dis-
covery, Cambridge, U.K.) and followed the manufacture’s
instructions. In brief, MSCs were seeded at a concentration of
2.5 × 104 cells/cm2 and cultured in standard conditions for
24 hours prior to transfection. Four to 5 hours before transfec-
tion, culture media is replaced by Optimem-reduced serum
media (Thermo Fisher Scientific). To perform the transfection,
the appropriate amount of Dharmafect per sample was always
added to the required amount of DMEM without antibiotics or
serum. A second mix was prepared by adding the proper
amount of GapmeR (30, 60, or 120 nM as stated), to the
appropriate volume of serum and antibiotics free DMEM. Both
mixtures were incubated for 5 minutes at room temperature
(RT). Recommended volumes of all reagents will depend on
the plating format. This information can be found at the man-
ufacture’s web page. The content of the GapmeR mix was
added on top of the Dharmafect mix dropwise and carefully
mixed by pipetting was incubated at RT for 20 minutes before
it was added to the cells dropwise.
To seed the cells in the alginate scaffolds, 105 cells per
scaffold were resuspended in a mixture containing both the
transfection agent and the correspondent amount of GapmeR
in DMEM without serum or antibiotics and applied directly to
the scaffold. Cells were allowed to attach to the scaffold for at
least 20 minutes. Longer incubation times of up to 24 hours
might be used if required. The following day, enough DMEM
supplemented with 10% FBS and 1% penicillin/streptomycin
was added to cover the scaffold. If the scaffold was to be
maintained in culture for further analysis, media was replaced
every 48 hours.
In Vivo Experiments
All surgical procedures were performed under isoflurane anes-
thesia in sterile conditions as previously described [28].
For the rat calvaria model, 16 female ovariectomized
Sprague–Dawley rats were used. The detailed procedure for
creating a calvaria defect has already been published [15]. The
rats were divided in four experimental groups named: BMP;
BMP Cells; BMP Cells GapmeR Ctrl (negative control GapmeR);
and BMP Cells GapmeR Smurf1 (GapmeR specific for Smurf1
silencing) for histological evaluation.
For the ectopic model, alginate scaffolds were implanted
subcutaneously in Sprague–Dawley females. Scaffolds were
seeded with un-transduced rMSCs or rMSCs transduced with
the Control (CTRL) or Smurf1 GapmeRs following the transfec-
tion conditions and experimental procedures previously
described for in situ transfection. Scaffolds with no cells were
also used as control. Scaffolds were incubated with the cells in
the standard growing media used for those cells a minimum of
20 minutes and a maximum of 24 hours before implantation.
Different combinations of scaffolds with different BMP doses
(0, 3, or 6 μg) and cells transduced with a Negative control
GapmeR or a Smurf1 GapmeR were prepared. Scaffolds
seeded with untransfected cells were used as negative control.
Prior to implantation in the animal, the different alginate scaf-
folds were transferred to a serum-free culture media and incu-
bated at 37C with rotation for 90 minutes and excess media
was removed before implantation. All different scaffolds
tested were surgically implanted in the same animal to avoid
individual variations. Four animals were used for this experi-
ment, each of them receiving eight different scaffolds. Inser-
tion of the scaffold was performed through a cut in the skin of
approximately 0.5 cm. To close the incision the skin was sta-
pled. The same experiment was carried out in four different
animals. Twelve weeks after the procedure, animals were
euthanized by CO2, implants were removed from the rats, and
fixed in 10% formaldehyde, decalcified, and embedded in par-
affin. Five microns sections were stained with H&E [29],
Masson–Goldner trichrome [30], or Sirius red [31] following
standard protocols.
For the rat calvaria model, 16 female ovariectomized
Sprague–Dawley rats were used. The detailed procedure for
creating a calvaria defect has already been published [15]. The
© 2019 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
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rats were divided in four experimental groups of four rats each
named: BMP (scaffold with BMP-2 and no cells); BMP + Cells
(scaffold with 6 μg BMP-2 and MSCs); BMP + Cells + GapmeR
Ctrl (scaffold with 6 μg BMP-2 and MSCs transfected with a
negative control GapmeR); and BMP + Cells + GapmeR Smurf1
(scaffold with 6 μg BMP-2 and MSCs transfected with a
GapmeR specific for Smurf1 silencing).
All the experiments were reviewed and approved by the
Animal Care Committee at the University of Cantabria and the
University of La Laguna.
Histology and Histomorphometrical Evaluation of
Calvarial Defect
Samples were prepared for histological analysis, as previously
described [32]. New bone formation was identified by
hematoxylin-erythrosin staining. The degree of new bone min-
eralization was assessed with VOF trichrome stain, in which
red staining indicates advanced mineralization, whereas less
mineralized, newly formed bone stains blue [33].
Image Analysis and Bone Quantification
Sections were analyzed by light microscopy (LEICA DM 4000B).
A region of interest (ROI) for quantitative evaluation of new
bone formation was defined as the area of the tissue within
the defect. The ROI consisted of a circular region of 50 mm2;
the center of which coincided with that of the defect site.
New bone formation was evaluated using between 8 and
10 sections of 8 μ in thickness obtained at different levels of
the calvaria defect. The newly formed bone inside the defect
site was identified histologically and the repaired area was
measured using a detection system based on color differences
with the computer-based image analysis software (Leica Q-win
V3 Pro-image analysis system, Barcelona, Spain). The percent-
age of repair was calculated applying the equation:
%repair =
newbone area
original defect area within theROI
× 100
Inmunofluorescence
For immunofluorescence assays, cells cultured into alginate
scaffolds were fixed with 4% paraformaldehyde for 1 hour at
RT followed by two washes with PBS1X for 5 minutes and
permeabilization with 0.5% Triton X-100 in PBS for 20 minutes.
For blocking unspecific binding, alginate scaffolds were incu-
bated in 3% BSA in PBS for 20 minutes and washed twice with
PBS 1X for 5 minutes. Scaffolds were incubated with the pri-
mary antibodies for 48 hours at 4C. Primary antibodies were
a rabbit monoclonal antibody against RUNX2 (DIL7F, Cell Sig-
naling Technology, Beverly, MA, http://www.cellsignal.com)
and a rabbit polyclonal against Collagen I (ab3471, Abcam,
Cambridge, U.K., http://www.abcam.com). After incubation
with the primary antibodies, samples were washed and incu-
bated with an anti-rabbit IgG conjugated with FITC (Jackson
InmunoResearch Laboratories, 11-095-045) for 1 hour in the
dark. Nuclei were detected with DAPI-like Hoechst. Scaffolds
were mounted in Prolong Gold (Invitrogen) and samples ana-
lyzed 24 hours later.
Fluorescence and Laser Scanning Microscopy
To quantify the GapmeR uptake after in situ transfection by
fluorescence microscopy, we used an epifluorescence micro-
scope (Axioplan Zeiss). Cells were staining with DAPI to visual-
ize the nucleus. At least 200 cells were counted for each of
the samples.
To quantify the percentage of fluorescent cells after the
transfection with the GapmeR, a total of 100 cells was scored
for each area analyzed. Total cell number corresponds to the
number of nuclei (stained with DAPI); a cell was considered
positive when it showed a clear green fluorescence due to the
presence of the FAM-labeled GapmeR.
Confocal microscopy was performed with an LSM510 laser
scanning microscope (Zeiss) and an A1R Microscope (Nikon).
Confocal Scans were acquired with the LSM510 software.
Immunohystochemistry
Immunohistochemical stainings were performed as previously
described [34] and anti-Col1a1 antibody (ab34710, Abcam). All
staining were performed on formalin-fixed, paraffin-embedded
tissue sections, which were deparaffinized and rehydrated
followed by incubation with the primary antibody.
Gene Expression Analyses
RNA isolation from cell cultures and cDNA synthesis was per-
formed as previously described [27]. Alpl and Runx2 gene
expression levels were measured by real-time qPCR using
Taqman assays (Thermo Fisher Scientific) using assays
Hs00758162_m1 and Taqman Hs00231692_m1, respectively.
Expression levels were calculated relative to GAPDH (Assay
reference Hs99999905_m1) or RPL13A (Assay reference
Hs04194366_g1) as 2−Δct.
Alkaline Phosphatase Activity Assay
MSCs were plated at 25 × 103 cells/cm2 and cultured for
3 days in the correspondent differentiation media with or
without the addition of BMP, as stated in the text. Determina-
tion of alkaline phosphatase activity in cell lysates was per-
formed as previously described [35].
Statistical Analysis
For all experiments, except for the rat calvaria experiment, sta-
tistical significance was determined by the Student’s t test.
Data are presented as means  standard error of the mean
values. For assaying the percentage of repair in the rat calvaria
model, statistical analyses were performed using SPSS 21.0
software. In this case, one-way analysis of variance (ANOVA)
and a Tukey multiple comparison posttest were used to com-
pare the overall performance of the different groups. Results
are expressed as mean  SD. Significance was set at p < .05.
RESULTS
Efficiency of a Lipoplex System for the Intracellular
Delivery of GapmeRs
In order to set up the conditions to attain a high cellular
intake of the GapmeR molecules with a minimal cellular toxic-
ity, increasing concentrations of GapmeR (30, 60, and 120 nM)
labeled with a fluorophore were mixed with a constant volume
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Figure 1. Setup of the locked nucleic acid antisense oligonucleotide (LNA-ASO) alginate scaffold system. (A): Flow cytometry profile of
C3H10T1/2 mesenchymal stem cells transduced with the control and Smurf1 LNA-ASOs. These molecules are designed to carry a fluo-
rophore and therefore expressing GFP. Numbers show the percentage of cells positive for GFP 48 hours after transduction in each case.
(B): PCR performed with a pair of oligonucleotides that specifically detects the Smurf1 transcript on C3H10T1/2 cells transduced with the
different GapmeRs. Values reflect averages of triplicate samples. The transcript levels were normalized to GAPDH and RLP13A1 for all
reactions. Bars represent standard error of the mean values. (C): Graph representing the percentages of fluorescent cells attached to the
alginate scaffold, as showed in the picture, per 100 cells counted. The average bar represents the average values from four independent
areas. (D): Specific PCR for the detection of the Smurf1 transcript indicates a high degree of silencing of this gene in the cells, transfected
with the Smurf1 GapmeR, and growing onto the scaffold. (E): Growth curves of C3H10T1/2 cultures transduced with the different
GapmeRs at different days of culture. The graph represents the absorbance of the cultures once treated with MTT. Values correspond to
three independent cultures in each case. (F): Inmunofluorescence study of Runx2 and collagen I expression in cells undergoing differentia-
tion in the microenvironment of the alginate scaffold. Runx2 analysis was performed at 4 days after the initiation of the induction. Col1A1
analysis was performed at day 10 of osteogenic differentiation. Cells seeded to the scaffolds growing in normal media were used as
control.
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of a lipidic transfection agent and used to transfect a mono-
layer culture of the murine MSC line C3H10T1/2. The use of
this MSC line as an alternative to rat MSCs for the initial set
up the transfection conditions would allow us to reduce the
number of animals used in the study, therefore complying with
the principles of Humane Experimentation. Flow cytometry
analysis showed that GapmeRs concentrations of just 30 nM
achieved more than 98% efficiency with both the control and
Smurf1 GapmeRs, compared to those treated only with the
lipidic agent (Neg. Control). Higher concentrations (60 and
120 nM) did not improve transfection efficiency (Fig. 1A).
Importantly, a concentration of 120 nM lead to high cell death
rates 24 hours after the transfection. Analysis of Smurf1 silenc-
ing in those samples showed an important reduction in Smurf1
expression when GapmeR concentrations of 60 and 120 nM
were used (Fig. 1B). Since the 60 nM concentration produced
slightly higher levels of gene silencing and showed no substan-
tial cell death after transfection, this concentration was chosen
for the subsequent procedures.
Since we aim to use MSCs in conjunction with an alginate
osteoconductive scaffold, we tested the in situ cellular uptake
of the GapmeR and the ability of the transfected cells to
attach and proliferate in the scaffold microenvironment. As
shown in Figure 1C, 48 hours after the transfection, fluores-
cent microscopy analysis showed a high percentage of fluores-
cent cells (87% on average) attached to the scaffold, indicating
that results from the in situ transfection at the scaffold are
comparable to those obtained in a monolayer culture. Subse-
quently, cells were isolated from the alginate scaffold to assay
Smurf1 silencing. Figure 1D displays a highly significant degree
of silencing when cells were transfected with the Smurf1
Gapmer compared to those transfected with the control
GapmeR. MTT analysis at different time points showed that
cells transfected with both the control and Smurf1 GapmeR
were able to proliferate in the scaffold microenvironment,
although small differences in the proliferation rate could be
detected between the two types of cells (Fig. 1E).
We next evaluated the suitability of our scaffold to
support osteogenic differentiation. To this end, we allowed
untransfected cells to differentiate in an osteoinductive media
for 21 days and tested the presence of osteogenic proteins
(Runx2 and Collagen type I) by immunofluorescence at
Figure 2. Bone regeneration in a calvarial critical size defect. (A): Sixteen female ovariectomized Sprague–Dawley were divided in four
experimental groups of four rats each (n = 4). (A–D): Semipanoramic representative images showing in the experimental groups BMP (A),
BMP Cells (B), BMP Cells LNA-ASO Ctrl, (C) and BMP Cells LNA-ASO Smurf1 (D) the repair response where newly formed bone (NB) can
be seen both on the margins and inside the defect. The images (E) and (F) show details at high magnification of the newly formed bone
in the BMP Cells LNA-ASO Ctrl (E) and BMP Cells LNA-ASO Smurf1 (F) groups. Observe the greater homogeneity and continuity in the
structure of the bone in the group BMP Cells LNA-ASO Smurf1 as well as larger areas of mineralization stained red (mature bone). Abbre-
viations: AdT, adipose tissue; CT, connective tissue; DS, defect site; NB, newly formed bone; IB, inmature bone; MB, mature bone. (A–D)
×25, (E, F) ×200. (B) Histomorphometrical analysis. Comparison of the percentages of repair among the different experimental groups by
means of a one-way ANOVA with Tukey multiple comparison posttest. Bar graph depicts percentages of repair at different experimental
time points. Bars represent means  SD, *p < .05.
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different time points. Runx2 was detected as early as day 4 in
cells undergoing osteogenic differentiation in alginate scaffolds
(Fig. 1F) whereas in cells growing in a normal media, Runx2
expression was not detectable. Type I collagen was also
observed in cells growing in differentiation media at a later
stage (14 days) (Fig. 1F).
In Vivo Assessment of Bone Formation by Smurf1-
Depleted rMSCs in an Osteoporotic Rat Calvaria Defect
Model
To assay the in vivo bone forming capacity of Smurf1-depleted
rMSCs, we used an alginate scaffold containing 6 μg of BMP-2
microspheres that would sustainably release BMP-2 to the site
of damage in a rat calvaria defect model. BMP-2 release from
microspheres in cumulative percentage was 20%  3.1% at
24 hours, 30%  1.9% at 4 days, 37%  4.4% at 7 days,
43%  6.3% at 14 days, and 55%  4.1% at 28 days.
The histological analysis 12 weeks postimplantation showed
new bone formation in all experimental groups, including the
BMP-2 only group (BMP), with an important degree of repair
defect (Fig. 2A, panels a–d). The repair response was quite
homogeneous in each of the implanted groups and was
observed both in the margins and inside of the defect (Fig. 2A,
panels a–d), with the BMP + Cells group showing the less new
bone formation inside the defect (Fig. 2A, panel b). The micro-
architecture of the repaired bone showed a fragmented
Figure 3. Hematoxylin/eosin and Masson-Goldner staining of subdermical implants in rats pictures show histological analysis of sections
obtained from decalcified implants (n = 4). Hematoxylin/eosin (A) and Masson–Goldner staining (B) showing mineralized matrix in light
pink and light blue respectively. Arrows indicate osteocytes-like cells surrounded by lacunae and immersed in the mineralized matrix.
Magnification: ×4 and ×8.
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appearance in most groups, with the exception of the BMP
group and BMP + Cells + Gapmer Smurf1 group, where areas of
new bone were observed that showed less fragmentation and
more homogeneous appearance (Fig. 2A, panels a and d). In
general, there was a low presence of adipose and connective
tissue, being the repaired bone structure quite similar to that of
normal bone. VOF staining technique showed that most of the
newly formed bone had a reddish-brown coloration (Fig. 2A,
panels e and f), compatible with a good degree of mineraliza-
tion (mature bone), being slightly higher in the BMP + Cells
+ Gapmer Smurf1 group (Fig. 2A, panel f).
The histomorphometric analysis of the defect area showed
repair percentages between 66% and 85% for the BMP + Cells
and BMP + Cells + Gapmer Smurf1 groups, respectively. The
group implanted with rMSC in which Smurf1 had been silenced
(BMP + Cells + Gapmer Smurf1), showed a repair percent sig-
nificantly higher with respect to the rest of the groups
(Fig. 2B).
In Vivo Assessment of Bone Formation of Smurf1
Depleted rMSCs in a Rat Ectopic Implantation Model
In order to exclusively analyze the contribution of transplanted
rMSCs to bone regeneration in the alginate scaffold system,
we used an ectopic in vivo system that would prevent rMSCs
mobilized from the surround tissue seeding the scaffold. For
this, we implanted the scaffolds subcutaneously in the back of
Sprague–Dawley rats. We also analyzed whether the rMSC
where Smurf1 have been silenced would show a stronger
response in terms of regeneration capacity that the control
cells, when cells were subjected to suboptimal doses of BMP-
2. To this end, rMSCs were seeded into scaffolds loaded with
different amounts of BMP-2 (3 and 6 μg), and transfected in
situ using the 60 nM GapmeR concentration previously chosen
to achieve maximum efficiency. These scaffolds loaded with
the transfected cells were then subcutaneously implanted in
the recipient animals. As control, we also performed the same
procedure with a mixture containing only the transfection
agent and rMSCs.
After 12 weeks, the implants were surgically removed and
the extent of new bone formation was analyzed by histological
techniques. Scaffolds loaded with the high dose of BMP-2
microspheres (6 μg) lead to a consistent bone formation inde-
pendently of whether the rMSCs had been transfected with a
control GapmeR or with a GapmeR for the silencing of Smurf1
(Supplementary Fig. S2). However, in the implants loaded with
a low dose of BMP-2 (3 μM), only those rMSCs transfected
with the Smurf1 GapmeR showed abundant and mature bone
matrix (Fig. 3, Hematoxilin/Eosin row). These areas of mature
Figure 4. Sirius red-polarization/fluorescence detection of collagen fibers and immunohistochemical analysis of subdermical implants in
rats. Pictures show analysis of sections obtained from decalcified implants (n = 4). (A): Polarization microscopy of Sirius red stained colla-
gen fibers, showing birefringence of collagen enriched areas. (B): Slides observed under green fluorescent showing the typical
autofluorescence of collagen fibers. (C): Immunohistochemistry analysis of the correspondent sections using a Col1a1 antibody where
arrows indicate regions rich in COL1a1. Magnification: ×4.
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bone also contained cells surrounded by an empty region,
resembling the morphology of osteocytes within osteocytic
lacunae. This result was also observed when samples were sta-
ined with Masson-Goldner technique (Fig. 3, Masson
Trichromic row), a widely used histological technique that
stains collagen in a blue color. Importantly, in this sample, the
Masson Trichromic technique showed extensive areas of red
staining, corresponding to mineralized bone, where osteocytes
with lacunae are also visible. This characteristic red coloration
could not be seen in the 3 μM scaffolds carrying MSC trans-
fected with the control GapmeR, but can be clearly detected
in scaffolds with BMP-2 6 μM, independently of the GapmeR
used to transfect the cells seeded (Supplementary Fig. S2).
Staining of the samples with Sirius Red allowed us to clearly
observe bright areas under polarized light, due to the
refringence of collagen fibers structured in an antiparallel posi-
tion, characteristic of the organized lamellar bone (Fig. 4, Sirius
Red). Additionally, the typical autofluorescence of bone was
also detected in these samples when observed under green
fluorescent light (Fig. 4, Green Fluorescent light).
Immunohistochemistry analysis of COL1A1 expression also
showed an enhanced expression of this protein in the scaffolds
seeded with rMSCs where Smurf1 has been silenced, con-
firming the histological results (Fig. 4, COL1A1 row).
It is important to highlight that, contrary to what we found
in the calvarial model, in this ectopic model, no bone tissue
formation was detected in the control scaffolds where no cells
were loaded, independently of the BMP-2 dose present in the
scaffold (Supplementary Fig. S3).
Smurf1 Silencing Increases the Osteogenic Potential of
hMSCs from Osteoporotic Patients
To test whether the silencing of Smurf1 has also a positive
effect on the bone forming potential of MSCs from osteopo-
rotic patients (hMSCs-OP), these cells were transfected with
the Smurf1 GapmeR and the control GapmeR using the previ-
ously established protocols. Transfected cells were grown in
an osteogenic induction media containing different doses of
BMP-2 (0, 10, and 50 ng/ml) to assess the expression of key
osteogenic genes in those conditions. In hMSCs-OP transfected
with the Smurf1 GapmeR and differentiated in the presence of
BMP-2, we detected a clear downregulation of Runx2 expres-
sion. Interestingly, these results can be readily observed at
BMP-2 concentrations 10 times inferior to those normally used
to promote osteogenic differentiation of MSCs in vitro
(Fig. 5A).
Analysis of Alpl expression in MSCs-OP where Smurf1 has
been silenced at only 10 days of differentiation showed a sig-
nificant increase of Alpl expression at the two BMP-2 concen-
trations assayed (Fig. 5B). Importantly, this difference was also
significant when the alkaline phosphatase activity of the same
samples was evaluated (Fig. 5C). Also in agreement with an
increased osteogenic capacity, Alizarin red staining showed an
important presence of calcium deposits in hMSCs-OP trans-
fected with the Smurf1 GapmeR after 2 weeks of osteogenic
differentiation compared to the same cells transfected with a
control GapmeR.
DISCUSSION
One of the main obstacles for the development of a successful
MSC-based therapy is to be able to promote engraftment and
osteogenic differentiation of the transplanted cells. Different
MSC modifications have been designed to achieve this point
[15, 36–38]. Our group has previously shown that silencing of
the ubiquitin ligase Smurf1 using a lentiviral vector carrying a
specific siRNA leads to a significant improvement of bone for-
mation [15]. Although genetic modification of MSCs by viral
transfection is highly efficient, designing clinical applications
based on this system is restricted due to important safety con-
cerns [39]. We have managed to overcome this problem by
transiently modifying MSCs using GapmeRs, a specific type of
LNA-ASOs with enhanced stability that represent a clinically
safe way to modify MSC gene expression [40, 41]. Although
Figure 5. Differentiation capacity of hMSC from osteoporotic patients. (A, B): Quantitative PCRs showing the relative expression levels
of different osteogenic markers (Runx2 and Alpl) in hMSCs from osteoporotic patients (MSC-OP) transfected with a control GapmeR and
a GapmeR for the silencing of Smurf1. Graphs show expression of the analyzed markers in the presence of different doses of BMP-2.
Values reflect averages of triplicate samples. (B) Graph showing a significant increase in the Alpl activity in MSC-OP treated with the
Smurf1 GapmeR and differentiated for 8 days in the presence of 10 ng/ml BMP-2. (C): Osteogenic differentiation of the same hMSCs-OP
transfected with the Smurf1 GapmeR and differentiated in the presence of 10 ng/ml BMP-2 as revealed by Alizarin red staining bars rep-
resent standard error of the mean values. p-Values are indicated.
© 2019 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
Wiley Periodicals, Inc. on behalf of AlphaMed Press
STEM CELLS TRANSLATIONAL MEDICINE
1314 Enhancing Bone Regeneration by Smurf1 Silencing
GapmeRs can be taken up in the cell unassisted through a pro-
cess known as gymnosis [42], this process implies the use of
extremely high concentrations of the GapmeR, incurring in
exceptionally high costs and, occasionally, important dose-
dependent effects [43, 44]. In our system, the combination of
GapmeRs with a noncytotoxic lipidic transfection agent
allowed us to reduce the quantity of these molecules needed
to grant the delivery to the target cell by 5,000–10,000 times,
from 300 μM used on average in gymnotic processes to
30–60 nM in the lipidic agent-assisted delivery. This important
reduction would dramatically increase their clinical safety at
the same time that would drop the costs of the procedure,
thus bypassing the main disadvantages linked the use of these
molecules. Using as low as 30–60 nM of a GapmeR specifically
designed to silence Smurf1, we have managed to obtain trans-
fection efficiencies close to 99% without noticeable cytotoxic-
ity, also achieving a significant silencing of the targeted gene.
We have shown that a single transient transfection with the
GapmeR is able to induce a significant level of silencing of the
target gene, enough to prime the MSCs for osteogenic differ-
entiation without the need of further treatments.
Although several methods combining MSCs with osteo-
genic factors and biocompatible scaffolds have been tested,
these methods are not free of limitations. These restrictions
are normally associated to the concomitant treatment with
high doses of BMP-2 needed to achieve the required thera-
peutic effect or to the low engraftment of the transplanted
MSCs. Whereas the use of low passages and specific culture
conditions has increased the success of MSCs engraftment,
there is currently an unmet medical need to develop strategies
to promote in vitro differentiation of transplanted MSCs
avoiding the adverse effects caused by the use of high doses
of BMP, which would include an increase in inflammatory cells
at the site of application, the rise in serum levels of anti-BMP
antibodies, generalized oedema, and the appearance of het-
erotrophic ossifications [13].
The use of scaffolds that sustainably and locally release
BMP-2 has already been shown to efficiently induce bone for-
mation [45–47]. Using these scaffolds in a rat calvaria model,
we detected a significant increase of bone regeneration when
the scaffolds were loaded with MSCs transfected with the
Smurf1 GapmeR, compared to the different control samples.
However, bone formation, although to a lesser extent, was
also detected when we used a BMP-2 scaffold with no cells,
the same scaffold harboring untransfected MSCs or MSCs
transfected with a control GapmeR. These results are not
completely unexpected, since the alginate scaffold is a suitable
backbone for infiltrating MSCs mobilized from the surrounding
skull tissue [48–50]. Our results would suggest that the
implanted MSCs could be stimulated by the sustained release
of BMP-2. Also, the amount of BMP-2 loaded into the scaffolds
in this assay (6 g) is able to elicit bone regeneration on its
own, masking the possible effect of Smurf1 silencing in this
system.
Unlike the calvaria system, the ectopic implantation model
offers the opportunity to assess exclusively the engraftment of
transplanted cells and the osteogenic effect of Smurf1 silenc-
ing. The subcutaneous localization of the scaffolds would pre-
clude the engraftment of endogenous MSCs coming from the
bone marrow, although it could not be discarded that a low
number of circulating MSCs could mobilize and reach the
scaffold through blood vessels [51]. Based on the results from
the calvaria experiment and in order to test whether Smurf1
silencing increases the response to BMP-2, scaffolds with two
different doses of BMP-2 (3 and 6 μg) were implanted at the
back of the animals. Analysis of these scaffolds showed that,
opposite to the calvaria model, no bone tissue has been pro-
duced in BMP-2 loaded scaffolds with any transplanted cells,
underscoring the use of this subcutaneous model for the
assessment of transplanted MSCs engraftment and differentia-
tion. Although all types of MSCs tested were able to form
bone tissue when seeded in scaffolds with 6 μg of BMP
(Supplementary Fig. S1), scaffolds with half the dose of BMP
(3 μg) were able to elicit the formation of a mature and miner-
alized bone matrix only when they were seeded with MSCs
where Smurf1 expression has been previously silenced. This
result clearly indicates that Smurf1 silencing is able to increase
the susceptibility of MSCs to BMP-2, allowing a significant
reduction of the dose of this cytokine needed to achieve a
therapeutic effect.
Directing cell fate after transplantation is specially chal-
lenging in aged and osteoporotic patients. Not only the osteo-
genic potential of MSC from those patients is importantly
reduced [52–55], but there are also several evidences pointing
to an inverse correlation between donor age and proliferative
capacity [56], and between donor age and responsiveness to
BMP [57], something particularly important in osteoporotic
individuals, since this disease is more prevalent in aged popu-
lation. It is important to note that both the animals used in
the calvaria experiment and the cells implanted in those ani-
mals were osteoporotic. These results underscore the regener-
ative potential of hMSCs where Smurf1 expression has been
silenced and encouraged us to test this potential in MSCs from
osteoporotic patients (hMSC-OP). We found that hMSC-OP
where Smurf1 expression has been silenced showed a signifi-
cant increase both in Alpl expression and Alpl activity, indicat-
ing an enhanced osteogenic activity in those cells compared to
the controls. This was corroborated by the increased deposi-
tion of calcium in culture under osteogenic conditions showed
by the Alizarin red staining. Previously we have shown that
Runx2 expression levels are increased in hMSCs from osteopo-
rotic patients [27]. Although Runx2 is an activator of important
osteogenic genes, its transcription levels need to be turned
down to allow terminal differentiation of osteoblast [58]. This
lack of Runx2 downregulation after the differentiation cascade
has been initiated and might actually preclude osteoblasts dif-
ferentiation in osteoporotic hMSCs [58]. In the present work,
we show that silencing of Smurf1 in hMSC-OP leads to a signif-
icant downregulation of Runx2. This would be in agreement
with our previous observations and the recently described role
of Smurf1 [18] in preventing Runx2 accumulation in osteoblast.
Interestingly, MSCs-OP where Smurf1 has been silenced were
able to undergo osteogenic differentiation in response to only
10 ng/ml of BMP-2, a dose 10 times lower than those nor-
mally used in other in vitro protocols (100 ng/ml) [52, 59].
INFUSE/InductOS (Medtronic/Wyet), an FDA-approved treat-
ment that has become very prominent in the clinic, uses an
absorbable collagen sponge to administer, directly to the site
of damage, a dose of BMP-2 in the milligram range [60]. Tak-
ing into account the volume of our scaffold and the BMP-2
doses used in the in vivo models presented here, BMP-2 con-
centration in the alginate scaffold were 60 and 120 μg/ml for
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the scaffolds loaded with 3 and 6 μg, respectively. These doses
are clearly inferior to those administered through the INFUSE/
InductOS system (1,500 μg/ml according to the product specifi-
cations). In addition, the silencing of Smurf1 expression has
allowed us to promote osteogenic differentiation of human
MSCs using BMP doses in the nanogram range, which implies
a 1 million times reduction of the dose used in clinic. There-
fore, our approach, based on the silencing of Smurf1 expres-
sion in hMSCs previously isolated from the patient, would
allow the enhancement of osteogenic differentiation in those
cells at low BMP doses.
CONCLUSION
The BMP-Smad signaling cascade is an effective therapeutic
target to promote bone formation. Other authors have previ-
ously tried to modulate this route by using systems that,
although highly effective, are not suitable for clinical use [61,
62]. Here, we have used an efficient and clinically safe
approach to enhance MSC response to BMP-2 and their thera-
peutic efficacy. The delivery of low doses of BMP-2 in a
sustained manner would avoid the alleged side effects linked
to the usage of BMPs. We have demonstrated that a single
transient transfection of a GapmeR specifically designed to
silence the expression of the Smurf1 ubiquitin ligase enhances
osteogenesis and mature bone formation in vivo. We propose
that the combined use of biocompatible scaffolds that sustain-
ably deliver low doses of BMP-2 and Smurf1 silencing using a
LNA-ASOs in the transplanted cells would be a promising strat-
egy for healing large areas of bone defect, contributing to
improvement of bone quality and preventing fractures.
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